Serotype diversity and reassortment between human and animal rotavirus strains

Implications for rotavirus vaccine programs

Jon R. Gentsch, Ashley R. Laird, Brittany Bielfelt, Dixie D. Griffin, K. Bányai, Madhu Ramachandran, Vivek Jain, Nigel A. Cunliffe, Osamu Nakagomi, Carl D. Kirkwood, Thea K. Fischer, Umesh D. Parashar, Joseph S. Bresee, Baoming Jiang, Roger I. Glass

Research output: Contribution to journalArticle

447 Citations (Scopus)

Abstract

The development of rotavirus vaccines that are based on heterotypic or serotype-specific immunity has prompted many countries to establish programs to assess the disease burden associated with rotavirus infection and the distribution of rotavirus strains. Strain surveillance helps to determine whether the most prevalent local strains are likely to be covered by the serotype antigens found in current vaccines. After introduction of a vaccine, this surveillance could detect which strains might not be covered by the vaccine. Almost 2 decades ago, studies demonstrated that 4 globally common rotavirus serotypes (G1-G4) represent >90% of the rotavirus strains in circulation. Subsequently, these 4 serotypes were used in the development of reassortant vaccines predicated on serotype-specific immunity. More recently, the application of reverse-transcription polymerase chain reaction genotyping, nucleotide sequencing, and antigenic characterization methods has confirmed the importance of the 4 globally common types, but a much greater strain diversity has also been identified (we now recognize strains with at least 42 P-G combinations). These studies also identified globally (G9) or regionally (G5, G8, and P2A[6]) common serotype antigens not covered by the reassortant vaccines that have undergone efficacy trials. The enormous diversity and capacity of human rotaviruses for change suggest that rotavirus vaccines must provide good heterotypic protection to be optimally effective.

Original languageEnglish
JournalJournal of Infectious Diseases
Volume192
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Sep 1 2005

Fingerprint

Rotavirus Vaccines
Rotavirus
Vaccines
Immunity
Rotavirus Infections
Antigens
Reverse Transcription
Serogroup
Nucleotides
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Serotype diversity and reassortment between human and animal rotavirus strains : Implications for rotavirus vaccine programs. / Gentsch, Jon R.; Laird, Ashley R.; Bielfelt, Brittany; Griffin, Dixie D.; Bányai, K.; Ramachandran, Madhu; Jain, Vivek; Cunliffe, Nigel A.; Nakagomi, Osamu; Kirkwood, Carl D.; Fischer, Thea K.; Parashar, Umesh D.; Bresee, Joseph S.; Jiang, Baoming; Glass, Roger I.

In: Journal of Infectious Diseases, Vol. 192, No. SUPPL. 1, 01.09.2005.

Research output: Contribution to journalArticle

Gentsch, JR, Laird, AR, Bielfelt, B, Griffin, DD, Bányai, K, Ramachandran, M, Jain, V, Cunliffe, NA, Nakagomi, O, Kirkwood, CD, Fischer, TK, Parashar, UD, Bresee, JS, Jiang, B & Glass, RI 2005, 'Serotype diversity and reassortment between human and animal rotavirus strains: Implications for rotavirus vaccine programs', Journal of Infectious Diseases, vol. 192, no. SUPPL. 1. https://doi.org/10.1086/431499
Gentsch, Jon R. ; Laird, Ashley R. ; Bielfelt, Brittany ; Griffin, Dixie D. ; Bányai, K. ; Ramachandran, Madhu ; Jain, Vivek ; Cunliffe, Nigel A. ; Nakagomi, Osamu ; Kirkwood, Carl D. ; Fischer, Thea K. ; Parashar, Umesh D. ; Bresee, Joseph S. ; Jiang, Baoming ; Glass, Roger I. / Serotype diversity and reassortment between human and animal rotavirus strains : Implications for rotavirus vaccine programs. In: Journal of Infectious Diseases. 2005 ; Vol. 192, No. SUPPL. 1.
@article{d8098e6b34564267b89f5ebe03f98756,
title = "Serotype diversity and reassortment between human and animal rotavirus strains: Implications for rotavirus vaccine programs",
abstract = "The development of rotavirus vaccines that are based on heterotypic or serotype-specific immunity has prompted many countries to establish programs to assess the disease burden associated with rotavirus infection and the distribution of rotavirus strains. Strain surveillance helps to determine whether the most prevalent local strains are likely to be covered by the serotype antigens found in current vaccines. After introduction of a vaccine, this surveillance could detect which strains might not be covered by the vaccine. Almost 2 decades ago, studies demonstrated that 4 globally common rotavirus serotypes (G1-G4) represent >90{\%} of the rotavirus strains in circulation. Subsequently, these 4 serotypes were used in the development of reassortant vaccines predicated on serotype-specific immunity. More recently, the application of reverse-transcription polymerase chain reaction genotyping, nucleotide sequencing, and antigenic characterization methods has confirmed the importance of the 4 globally common types, but a much greater strain diversity has also been identified (we now recognize strains with at least 42 P-G combinations). These studies also identified globally (G9) or regionally (G5, G8, and P2A[6]) common serotype antigens not covered by the reassortant vaccines that have undergone efficacy trials. The enormous diversity and capacity of human rotaviruses for change suggest that rotavirus vaccines must provide good heterotypic protection to be optimally effective.",
author = "Gentsch, {Jon R.} and Laird, {Ashley R.} and Brittany Bielfelt and Griffin, {Dixie D.} and K. B{\'a}nyai and Madhu Ramachandran and Vivek Jain and Cunliffe, {Nigel A.} and Osamu Nakagomi and Kirkwood, {Carl D.} and Fischer, {Thea K.} and Parashar, {Umesh D.} and Bresee, {Joseph S.} and Baoming Jiang and Glass, {Roger I.}",
year = "2005",
month = "9",
day = "1",
doi = "10.1086/431499",
language = "English",
volume = "192",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Serotype diversity and reassortment between human and animal rotavirus strains

T2 - Implications for rotavirus vaccine programs

AU - Gentsch, Jon R.

AU - Laird, Ashley R.

AU - Bielfelt, Brittany

AU - Griffin, Dixie D.

AU - Bányai, K.

AU - Ramachandran, Madhu

AU - Jain, Vivek

AU - Cunliffe, Nigel A.

AU - Nakagomi, Osamu

AU - Kirkwood, Carl D.

AU - Fischer, Thea K.

AU - Parashar, Umesh D.

AU - Bresee, Joseph S.

AU - Jiang, Baoming

AU - Glass, Roger I.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - The development of rotavirus vaccines that are based on heterotypic or serotype-specific immunity has prompted many countries to establish programs to assess the disease burden associated with rotavirus infection and the distribution of rotavirus strains. Strain surveillance helps to determine whether the most prevalent local strains are likely to be covered by the serotype antigens found in current vaccines. After introduction of a vaccine, this surveillance could detect which strains might not be covered by the vaccine. Almost 2 decades ago, studies demonstrated that 4 globally common rotavirus serotypes (G1-G4) represent >90% of the rotavirus strains in circulation. Subsequently, these 4 serotypes were used in the development of reassortant vaccines predicated on serotype-specific immunity. More recently, the application of reverse-transcription polymerase chain reaction genotyping, nucleotide sequencing, and antigenic characterization methods has confirmed the importance of the 4 globally common types, but a much greater strain diversity has also been identified (we now recognize strains with at least 42 P-G combinations). These studies also identified globally (G9) or regionally (G5, G8, and P2A[6]) common serotype antigens not covered by the reassortant vaccines that have undergone efficacy trials. The enormous diversity and capacity of human rotaviruses for change suggest that rotavirus vaccines must provide good heterotypic protection to be optimally effective.

AB - The development of rotavirus vaccines that are based on heterotypic or serotype-specific immunity has prompted many countries to establish programs to assess the disease burden associated with rotavirus infection and the distribution of rotavirus strains. Strain surveillance helps to determine whether the most prevalent local strains are likely to be covered by the serotype antigens found in current vaccines. After introduction of a vaccine, this surveillance could detect which strains might not be covered by the vaccine. Almost 2 decades ago, studies demonstrated that 4 globally common rotavirus serotypes (G1-G4) represent >90% of the rotavirus strains in circulation. Subsequently, these 4 serotypes were used in the development of reassortant vaccines predicated on serotype-specific immunity. More recently, the application of reverse-transcription polymerase chain reaction genotyping, nucleotide sequencing, and antigenic characterization methods has confirmed the importance of the 4 globally common types, but a much greater strain diversity has also been identified (we now recognize strains with at least 42 P-G combinations). These studies also identified globally (G9) or regionally (G5, G8, and P2A[6]) common serotype antigens not covered by the reassortant vaccines that have undergone efficacy trials. The enormous diversity and capacity of human rotaviruses for change suggest that rotavirus vaccines must provide good heterotypic protection to be optimally effective.

UR - http://www.scopus.com/inward/record.url?scp=23944461107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944461107&partnerID=8YFLogxK

U2 - 10.1086/431499

DO - 10.1086/431499

M3 - Article

VL - 192

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 1

ER -